Table 2.
MNPs | Magnetic | Mechanism | Model | Results | Toxicity | Ref. |
---|---|---|---|---|---|---|
Au + Ni80Fe20 (permalloy) 1 μm radius disk-shaped |
Dynamic 1 T at 20 Hz rotating |
Vortex shaped rotation | In vivo mice glioma | Increased survival | No change in histology No side effects |
[50] |
pEGFP/p53 conjugated | Static | Gene therapy + magnetofection | In vitro BBB + glioblastoma | Increased induced apoptosis | - | [51] |
Aptamer conjugated dextran coated | Alternate 9.55 kA/m at 1 Hz |
3D Rotating nanosurgeons | In vitro glioblastoma | Increased induced apoptosis | - | [52] |
Octadecyl-quaternized carboxymethyl chitosan | Static 0.5 T | Delivery loaded paclitaxel | In vivo rats glioma | Increased survival Prolonged bioavailability |
Reduced side-effects | [53] |
Inhibitor of metalloproteinase-1 conjugated | Static 0.8 T | Crossing BBB and regulation of metalloproteinases | In vitro BBB + HIV infection | Recovery in spine density ROS and HIV infection level decrease |
Unchanged TEER and cells viability | [54] |
Bilayers: Tenofovir + dextran Sulphate + vorinostat |
Static 0.08 T 6 h |
Crossing BBB and antiretroviral therapy | In vitro BBB + HIV infection | HIV infection level decrease Prolonged bioavailability |
Unchanged TEER and cells viability | [55] |
Azidothymidine 5′-triphosphate loaded CoFe2O4@BaTiO3 | Static 22 Oe/cm 6 h Alternate 66 Oe at 100 Hz 5 min |
Crossing BBB and controlled release of antiviral drug | In vitro BBB + HIV infection | Functional and structural integrity of the drug after the release | High cell viability | [56] |
Beclin1 siRNA binded CoFe2O4@BaTiO3 | Static 0.8 T 3 h |
Crossing BBB and regulate autophagy | In vitro BBB + HIV infection | Attenuate HIV-1 replication and viral-induced inflammation | Unchanged TEER and occludin expression | [57] |
Morphine antagonist, CTOP conjugated | Static 0.5 T | Crossing BBB and drug delivery | In vitro BBB + HIV infection | Recovery in spine density Prevention of morphine induced apoptosis |
High cell viability Unchanged TEER |
[59] |
PEG shell | Alternate 15 kA/m 500 KHz |
Heat-sensitive capsaicin receptor TRPV1 activated by magnetothermal genetic stimulation | In vitro neurons + in vivo mice | On demand activation of neurons in deep nuclei (VTA) | Lower glial activation and macrophage accumulation compared to implant | [60] |
CoFe2O4-BaTiO3 GMO coated | Static 3000 Oe/cm Alternate 100 Oe at 0–20 Hz |
Crossing and concentrate in brain then modulate neural activity | In vitro + in vivo mice | EEG detectable modulation activity of 1 mV | No toxicity for astrocytes and blood cells in vitro | [61] |
Co-ferrite core and Mn-ferrite shell Polymer PMA coated |
Alternate 7–30 kA/m at 412–570 KHz |
Heat-sensitive capsaicin receptor TRPV1 activated by magnetothermal genetic stimulation | In vitro neurons + in vivo mice | On demand evoked motor cortex ambulation, striatum rotation or freezing | - | [62] |
GFP-tagged ferritin | Alternate 23–31 mT at 465 kHz |
Heat-sensitive capsaicin receptor TRPV1 activated by magnetothermal genetic stimulation | In vitro neurons + in vivo mice | Glucose-sensing hypothalamus neurons modulate feed behavior | - | [63] |
Starch-coated | Static 150 mT | Magnetic force open neuron channels | In vitro neuron | Mechanical opening of N-type mechanosensitive Ca2+ channels |
Reversibility of opening | [65] |
Starch and chitosan coated | Static 150 mT | Magnetic force open neuron channels | In vitro neuron | Mechanical opening of N-type mechanosensitive Ca2+ channels |
Unchanged cell viability, reversibility of opening | [66] |
Ferumoxide-labeled human neural stem cells | Static 0.32 T | Magnetic targeting | In vivo stroke rats | Better targeting and recovery in a stroke model | Unchanged differentiation into neurons or astrocytes | [68,69] |
Dextran-coated | Alternate 1–6 A at 0.25–2 Hz 10 min |
Osmotin load targeting in hippocampus and delivery | In vitro + in vivo AD rats | Memory improvement Reduced protein accumulation and synaptotoxicity |
Unchanged viability No apoptosis No BBB leakage |
[70,71] |
Oleic acid-coated | 3 days | Gene therapy delivery Alpha-Synuclein RNAi Plasmid | In vitro + in vivo PD mice | Motor improvement Reduced neurodegeneration |
No organ damage Normal blood test 12 days |
[73] |
Uncoated Fe3O4 | Alternate 2 h/d for 1 week |
Synergic effect of magnetic stimulation and MNPs | In vivo PD rats | Motor improvement/recover feeding behavior Reduced ROS and lesion volume |
Normal mitochondrial activity | [74] |